Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes

Regulatory T cells (Tregs) constitute an attractive therapeutic target given their essential role in controlling autoimmunity. However, recent animal studies provide evidence for functional heterogeneity and lineage plasticity within the Treg compartment. To understand better the plasticity of human Tregs in the context of type 1 diabetes, we characterized an IFN-γ–competent subset of human CD4+CD127lo/−CD25+ Tregs. We measured the frequency of Tregs in the peripheral blood of patients with type 1 diabetes by epigenetic analysis of the Treg-specific demethylated region (TSDR) and the frequency of the IFN-γ+ subset by flow cytometry. Purified IFN-γ+ Tregs were assessed for suppressive function, degree of TSDR demethylation, and expression of Treg lineage markers FOXP3 and Helios. The frequency of Tregs in peripheral blood was comparable but the FOXP3+IFN-γ+ fraction was significantly increased in patients with type 1 diabetes compared to healthy controls. Purified IFN-γ+ Tregs expressed FOXP3 and possessed suppressive activity but lacked Helios expression and were predominately methylated at the TSDR, characteristics of an adaptive Treg. Naive Tregs were capable of upregulating expression of Th1-associated T-bet, CXCR3, and IFN-γ in response to IL-12. Notably, naive, thymic-derived natural Tregs also demonstrated the capacity for Th1 differentiation without concomitant loss of Helios expression or TSDR demethylation.

[1]  Thorsten Dickhaus,et al.  Epigenetic quantification of tumor-infiltrating T-lymphocytes , 2011, Epigenetics.

[2]  Y. Belkaid,et al.  Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cells , 2010, The Journal of Immunology.

[3]  W. Paul,et al.  Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells , 2010, Science.

[4]  S. Glišić,et al.  Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls , 2010, Cell and Tissue Research.

[5]  Y. Belkaid,et al.  Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. , 2009, Immunity.

[6]  A. Rudensky,et al.  CD4+ Regulatory T Cells Control TH17 Responses in a Stat3-Dependent Manner , 2009, Science.

[7]  J. Rowe,et al.  Allogeneic induced human FOXP3+IFN‐γ+ T cells exhibit selective suppressive capacity , 2009, European journal of immunology.

[8]  J. Bluestone,et al.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.

[9]  Jonathan H. Esensten,et al.  T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function1 , 2009, The Journal of Immunology.

[10]  M. Battaglia,et al.  The fate of human Treg cells. , 2009, Immunity.

[11]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[12]  J. Bluestone,et al.  Plasticity of CD4(+) FoxP3(+) T cells. , 2009, Current opinion in immunology.

[13]  James L Riley,et al.  Human T regulatory cell therapy: take a billion or so and call me in the morning. , 2009, Immunity.

[14]  R. Flavell,et al.  How are T(H)1 and T(H)2 effector cells made? , 2009, Current opinion in immunology.

[15]  R. Andreesen,et al.  Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation , 2009, European journal of immunology.

[16]  Daniel J. Campbell,et al.  T-bet controls regulatory T cell homeostasis and function during type-1 inflammation , 2009, Nature Immunology.

[17]  G. Szot,et al.  Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes , 2009, Diabetes.

[18]  A. Keegan.  Faculty Opinions recommendation of Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. , 2009 .

[19]  Fabian Model,et al.  Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. , 2009, Cancer research.

[20]  C. Benoist,et al.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.

[21]  J. Buckner,et al.  The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[22]  Chen Dong,et al.  Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. , 2008, Immunity.

[23]  J. Bluestone,et al.  Human regulatory T cells: role in autoimmune disease and therapeutic opportunities , 2008, Immunological reviews.

[24]  K. Kretschmer,et al.  DNA methylation controls Foxp3 gene expression , 2008, European journal of immunology.

[25]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[26]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[27]  E. Shevach,et al.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. , 2007, Blood.

[28]  M. Atkinson,et al.  Treg in type 1 diabetes , 2007, Cell Biochemistry and Biophysics.

[29]  M. Roncarolo,et al.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. , 2007, International immunology.

[30]  Edgar Schmitt,et al.  Epigenetic Control of the foxp3 Locus in Regulatory T Cells , 2007, PLoS biology.

[31]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[32]  R. Andreesen,et al.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. , 2006, Blood.

[33]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[34]  T. Huang,et al.  T-bet Binding to Newly Identified Target Gene Promoters Is Cell Type-independent but Results in Variable Context-dependent Functional Effects*♦ , 2006, Journal of Biological Chemistry.

[35]  A. Rudensky,et al.  Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Ziegler.  FOXP3: of mice and men. , 2006, Annual review of immunology.

[37]  M. Roncarolo,et al.  Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. , 2005, Blood.

[38]  J. Bluestone,et al.  Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Stockinger,et al.  IL-10-Secreting Regulatory T Cells Do Not Express Foxp3 but Have Comparable Regulatory Function to Naturally Occurring CD4+CD25+ Regulatory T Cells 1 , 2004, The Journal of Immunology.

[40]  J. Bach.  Autoimmune Diseases as the Loss of Active “Self‐Control” , 2003, Annals of the New York Academy of Sciences.

[41]  M. Atkinson,et al.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment , 2001, The Lancet.

[42]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[43]  M. Gately,et al.  IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. , 1993, Journal of immunology.

[44]  M. Noris,et al.  Natural versus adaptive regulatory T cells. , 2005, Contributions to nephrology.